Purpose of review: HIV/AIDS and COVID-19 have been the major pandemics overwhelming our times. Given the enduring immune disfunction featuring people living with HIV (PLWH) despite combination antiretroviral therapy (cART), concerns for higher incidence and severity of SARS-CoV-2 infection as well as for suboptimal responses to the newly developed vaccines in this population arose early during the pandemics. Herein, we discuss the complex interplay between HIV and SARS-CoV-2, with a special focus on the immune responses to SARS-CoV-2 natural infection and vaccination in PLWH. Recent findings: Overall, current literature shows that COVID-19 severity and outcomes may be worse and immune responses to infection or vaccination lower in PLWH with poor CD4 + T-cell counts and/or uncontrolled HIV viremia. Data regarding the risk of post-acute sequelae of SARS-CoV-2 infection (PASC) among PLWH are extremely scarce, yet they seem to suggest a higher incidence of such condition. Scarce immunovirological control appears to be the major driver of weak immune responses to SARS-CoV-2 infection/vaccination and worse COVID-19 outcomes in PLWH. Therefore, such individuals should be prioritized for vaccination and should receive additional vaccine doses. Furthermore, given the potentially higher risk of developing long-term sequelae, PLWH who experienced COVID-19 should be ensured a more careful and prolonged follow-up.

Immunologic Interplay Between HIV/AIDS and COVID-19: Adding Fuel to the Flames? / M. Augello, V. Bono, R. Rovito, C. Tincati, G. Marchetti. - In: CURRENT HIV/AIDS REPORTS. - ISSN 1548-3568. - (2023 Jan 21), pp. 1-25. [10.1007/s11904-023-00647-z]

Immunologic Interplay Between HIV/AIDS and COVID-19: Adding Fuel to the Flames?

M. Augello
Primo
;
V. Bono
Secondo
;
R. Rovito;C. Tincati
Penultimo
;
G. Marchetti
Ultimo
2023

Abstract

Purpose of review: HIV/AIDS and COVID-19 have been the major pandemics overwhelming our times. Given the enduring immune disfunction featuring people living with HIV (PLWH) despite combination antiretroviral therapy (cART), concerns for higher incidence and severity of SARS-CoV-2 infection as well as for suboptimal responses to the newly developed vaccines in this population arose early during the pandemics. Herein, we discuss the complex interplay between HIV and SARS-CoV-2, with a special focus on the immune responses to SARS-CoV-2 natural infection and vaccination in PLWH. Recent findings: Overall, current literature shows that COVID-19 severity and outcomes may be worse and immune responses to infection or vaccination lower in PLWH with poor CD4 + T-cell counts and/or uncontrolled HIV viremia. Data regarding the risk of post-acute sequelae of SARS-CoV-2 infection (PASC) among PLWH are extremely scarce, yet they seem to suggest a higher incidence of such condition. Scarce immunovirological control appears to be the major driver of weak immune responses to SARS-CoV-2 infection/vaccination and worse COVID-19 outcomes in PLWH. Therefore, such individuals should be prioritized for vaccination and should receive additional vaccine doses. Furthermore, given the potentially higher risk of developing long-term sequelae, PLWH who experienced COVID-19 should be ensured a more careful and prolonged follow-up.
AIDS; COVID-19; HIV; Immune responses; SARS-CoV-2; Vaccines
Settore MED/17 - Malattie Infettive
CAR_RIC20GMARC_01 - Joint artificial intelligence and protein structure modelling to guide largescale screenings for anti-SARS-Cov2 neutralizing antibodies (CoroNAId) - MARCHETTI, GIULIA CARLA - CAR_RIC - Bandi Fondazione Cariplo - 2020
CAR_RIC20GMARC_02 - Targeting acute immune responses and aberrant inflammation to improve the clinical outcome of elderly SARS-Cov-2 infected patients (IMMU-COV-AGING) - MARCHETTI, GIULIA CARLA - CAR_RIC - Bandi Fondazione Cariplo - 2020
FON_NAZ20ADARM_01 - Pazienti HIV+ ed epidemia da Covid-19 - D'ARMINIO MONFORTE, ANTONELLA - FON_NAZ - Bandi Altre Fondazioni - 2020
Article (author)
File in questo prodotto:
File Dimensione Formato  
s11904-023-00647-z.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 2.89 MB
Formato Adobe PDF
2.89 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/951818
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact